Page last updated: 2024-09-05

sorafenib and withaferin a

sorafenib has been researched along with withaferin a in 3 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(withaferin a)
Trials
(withaferin a)
Recent Studies (post-2010) (withaferin a)
6,5207305,25159022454

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)withaferin a (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 20.585
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)0.047
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)0.047
Transcription factor p65Homo sapiens (human)0.047

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN1
Chakraborti, A; Kanthaje, S; Kaur, H; Kaur, R; Makol, A; Sharma, S1
Duan, J; Fan, L; Jiang, B; Liu, S; Tan, Y; Yin, H; Zhang, Y; Zhao, X1

Other Studies

3 other study(ies) available for sorafenib and withaferin a

ArticleYear
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    American journal of surgery, 2012, Volume: 204, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides

2012
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
    Clinical and molecular hepatology, 2020, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Hepatocellular; Cell Survival; Chromatography, High Pressure Liquid; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Proteomics; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vimentin; Withanolides

2020
Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
    Toxicology mechanisms and methods, 2023, Volume: 33, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Ferroptosis; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Sorafenib

2023